Empower Pharmacy

What Empower Pharmacy does

Empower Pharmacy is a Houston, Texas-based compounding pharmacy operating as both a 503A patient-specific compounding pharmacy and an FDA-registered 503B outsourcing facility — one of very few compounders with both registrations under a single corporate entity (legal name: Empower Clinic Services, L.L.C.). Founded in 2009 by CEO Shaun Noorian, the company operates a 380,000-square-foot manufacturing footprint in Houston plus a second sterile-manufacturing facility in East Windsor, New Jersey, acquired from Eugia US LLC (an Aurobindo Pharma subsidiary) for $52 million in May 2024. It is licensed to dispense in all 50 U.S. states plus Puerto Rico and serves more than 33,000 prescribers and several million patients.

The product portfolio spans compounded medications in men's and women's health, hormone replacement, weight management (notably GLP-1 injectable and orally disintegrating formulations of semaglutide and tirzepatide), longevity, IV therapy, dermatology, sexual health, mental health, and peptides, alongside distribution of commercial products such as Omnitrope and Tralement injectables. Distribution runs through prescriber direct orders (503A), a 503B bulk portal (officeuse.empowerpharmacy.com), pharmacy-to-pharmacy supply, telehealth-company partnerships, and a patient-facing mobile app supporting nationwide ground and overnight shipping with refrigerated cold-chain capability. Technology infrastructure includes Datadog, Salesforce, Revenue.io, and other AI/analytics vendors, with a dedicated technology transformation under CTO Goldi Goel (formerly of Amazon Pharmacy and Albertsons).

The business model is transaction-based, pay-as-you-go, with Empower deliberately not accepting insurance — eliminating PBM/payer middlemen to offer compounded medications at materially lower prices than branded equivalents (e.g., compounded semaglutide at $150–$400/month versus branded Ozempic/Wegovy at $900–$1,300/month). Growth has been funded primarily through operating cash flow and a senior subordinated debt facility from LO3 Capital (September 2023); no equity rounds are disclosed. Revenue grew from approximately $119 million in 2022 to roughly $370–$400 million in 2024, supporting an Inc. 5000 ranking in 2025. The company faces material regulatory and legal headwinds, including an FDA warning letter, an East Windsor Form 483 documenting microbial contamination, multi-state disciplinary actions, and active litigation from Eli Lilly over compounded tirzepatide.

Name

Empower Pharmacy

Legal name

Empower Clinic Services, L.L.C.

Website

https://empowerpharmacy.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Houston-based Empower Pharmacy operates the largest U.S. 503A compounding pharmacy and an FDA-registered 503B outsourcing facility, serving over 33,000 prescribers and millions of patients across all 50 states with personalized and bulk compounded medications on a direct-pay basis.

Ownership category

akta.pro rank

Product category

Compounding Pharmacy Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Pharmacies and Drug Retailers (456110)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Compounding Pharmacies (Sterile/Non-Sterile) (HLAFALAE)

akta.pro secondary industries

Specialty Pharmacy & Complex Therapy Management Platforms (HLACAKAG), Injectables & Specialty Medication Support (e.g., insulin, biologics) (HSABALAG)

Keywords

• Compounding pharmacy services
• 503B outsourcing facility
• Sterile injectable manufacturing
• Personalized medication compounding
• Bulk pharmaceutical distribution

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Compounded Medications - 503A: Compounding pharmacy services for individual patient prescriptions submitted by healthcare providers. Serves patients across all 50 states with personalized medications in various therapeutic areas including hormone replacement, weight management, dermatology, mental health, longevity, and more. Does not accept insurance, eliminating middlemen to provide affordable medications.
2. Compounded Medications - 503B Bulk/Outsourcing: Bulk compounding and outsourcing facility services for healthcare providers who administer medications in-office. 503B facilities produce larger batches for provider office use. Expansion with new 503B outsourcing facility in Houston in March 2025.
3. Commercial Pharmaceutical Products: Distribution of commercially manufactured pharmaceutical products alongside compounded formulations, including products like Zomacton Injection, Omnitrope Injection, Tralement Injection, and other commercial medications listed in the product catalog.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

Empower Pharmacy compounds personalized medications under Section 503A for individual patient prescriptions submitted by licensed prescribers across all 50 U.S. states, and produces bulk sterile and non-sterile compounded medications under Section 503B for healthcare provider offices and partner pharmacies. Its product portfolio spans hormone replacement, GLP-1 weight management (semaglutide, tirzepatide, including ODT formulations), men's and women's health, longevity, IV therapy, dermatology, peptides, and mental health, complemented by select commercial pharmaceutical products distributed through its pharmacy license. Orders are placed through a digital portal, mobile app, or API and shipped nationwide.

Product overview

Empower Pharmacy is the nation's premier 503A compounding pharmacy and FDA-registered 503B outsourcing facility, offering a comprehensive portfolio of compounded and commercial pharmaceutical products. The company operates as a dual-model pharmacy: its 503A services compound patient-specific medications for individuals with prescriptions from healthcare providers across all 50 states, while its 503B facility produces bulk compounded medications for healthcare provider offices. The product portfolio spans multiple therapeutic categories including Men's Health (testosterone preparations, enclomiphene), Women's Health (hormone therapies), Weight Management (GLP-1 medications including semaglutide and tirzepatide in both injectable and oral formulations), Longevity (NAD+ injections, growth hormone), IV Therapy (trace element injections, vitamin injections), Dermatology (copper peptide serums), Sexual Health, Mental Health, and Peptides. The company also distributes commercial pharmaceutical products and provides digital platforms including a mobile app and bulk ordering portal. Key trending products include Semaglutide/Cyanocobalamin Injection, Tirzepatide/Niacinamide Injection, Testosterone Cypionate Injection, NAD+ Injection, Sermorelin Acetate products, and GHK-Cu formulations. The company serves over 33,000 prescribers and several million patients nationwide.

Differentiator

Problem solved

Functional benefit

Products and services

• 503A Compounding Pharmacy Services Patient-specific compounding service in which licensed prescribers submit individual prescriptions for customized medications (sterile and non-sterile) that Empower compounds and dispenses to patients nationwide.
• 503B Outsourcing Facility Services Bulk compounding and outsourcing facility service that produces larger batches of sterile and non-sterile medications for healthcare providers to administer in-office and for partner pharmacies to redistribute.
• Semaglutide / Cyanocobalamin Injection Compounded GLP-1 receptor agonist injectable combining semaglutide with cyanocobalamin (Vitamin B12), prescribed for weight management by licensed providers.
• Tirzepatide / Niacinamide Injection Compounded dual GLP-1/GIP receptor agonist injectable combining tirzepatide with niacinamide, prescribed for weight management.
• Tirzepatide Oral Dissolving Tablet (ODT) Orally disintegrating tablet formulation of tirzepatide, providing a non-injectable alternative for weight management therapy.
• Testosterone Cypionate Injection Compounded injectable testosterone used for hormone replacement therapy in men with low testosterone.
• NAD+ Injection (Lyo) Lyophilized (freeze-dried) injectable formulation of nicotinamide adenine dinucleotide (NAD+) for longevity and anti-aging therapy.
• Sermorelin Acetate Injection Compounded injectable growth hormone-releasing peptide (GHRP) used for hormone optimization therapy.
• Sermorelin Acetate ODT Orally disintegrating tablet formulation of sermorelin acetate for hormone optimization.
• HCG Injection Human chorionic gonadotropin (HCG) injectable used for fertility treatments and hormone support.
• Enclomiphene Citrate Capsules Compounded selective estrogen receptor modulator capsules used to support testosterone in men.
• Nandrolone Decanoate Injection Compounded anabolic steroid injection used for hormone replacement and select medical conditions.
• Omnitrope Injection Commercially manufactured recombinant human growth hormone (somatropin) distributed through Empower's pharmacy license.
• Tralement Injection Commercially manufactured trace element injection (zinc, copper, manganese, chromium) for parenteral nutrition.
• GHK-Cu Facial Serum Copper peptide topical facial serum formulated to improve the appearance of skin texture.
• GHK-Cu Scalp Solution Copper peptide topical scalp solution formulated to support healthier-looking hair and scalp.
• Empower Pharmacy Mobile App iOS and Android mobile application that allows patients to view prescription information, request refills, securely message Empower staff, and manage pharmacy accounts.
• Bulk Portal (503B Ordering) Self-serve bulk ordering portal at officeuse.empowerpharmacy.com for healthcare providers and partner pharmacies to order 503B compounded medications.

Quantifiable outcome

• Revenue grew from approximately $119 million (2022) to over $370 million (2024), representing significant growth trajectory
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

Partnerships

Two partnerships are on record, tiered minor and core.

• GuardianMDminorStrategic or Co-development Partner · 4 February 2025Empower Pharmacy partnered with GuardianMD to host a 90-minute functional medicine webinar on February 4, 2025 at 6:30 PM EST. Dr. Chris Seitz, founder of GuardianMD, presented on functional medicine vs. traditional medicine. Jason Robbins of Empower Pharmacy hosted the session, which offered free nursing CE credits. GuardianMD supports over 600 clinics across the United States and provides remote medical oversight to non-physician clinicians.
• Eugia US LLC (Aurobindo Pharma Ltd.)coreOthers · 1 May 2024Empower Pharma acquired manufacturing assets from Eugia US LLC, a subsidiary of Aurobindo Pharma Ltd., in May 2024 for $52 million to strengthen capacity in sterile medication production for maternal health therapeutics. The acquisition established Empower's 503B outsourcing facility in East Windsor, New Jersey. Edgar Gonzalez, VP Deputy General Counsel, led the acquisition, workforce integration, regulatory licensing, and staffing for the new facility.

Scale indicators13 records

Recent moves8 records

Expansion highlights6 records

Emerging players

• Belmar Pharmacy: Belmar is a national 503A compounding pharmacy specializing in hormone replacement, peptides, and integrative therapies. It competes with Empower in personalized hormone and longevity categories across multiple states.
• Ro (Roman): Ro is a direct-to-patient telehealth platform offering compounded and personalized medications (including weight management) through its own pharmacy operations. It overlaps with Empower on therapeutic categories and represents both a partner and a competitor for prescriber-driven volume.
• Hims & Hers Health: Hims & Hers is a major telehealth distributor of compounded GLP-1 weight-loss medications and personalized therapies, sourcing from compounding pharmacies including Empower. It is an important channel partner and adjacent competitor in personalized medicine.

Direct peers

• QuVa Pharma: QuVa Pharma is a leading FDA-registered 503B outsourcing facility producing sterile compounded medications for hospitals and health systems. It is the most direct 503B peer to Empower's outsourcing operations, competing for the same hospital and provider customers.
• Triangle Compounding Pharmacy: Triangle Compounding is a 503A pharmacy producing personalized sterile and non-sterile preparations (including hormone and weight management therapies) for prescribers and patients across multiple U.S. states. It is a direct therapeutic-area competitor to Empower's 503A catalog.
• Olympia Pharmaceuticals: Olympia operates both 503A compounding pharmacy and 503B outsourcing facility operations serving practitioners and office-based practices. Its dual-model structure and prescriber-direct distribution closely mirror Empower's go-to-market.
• Central Admixture Pharmacy Services (CAPS / B. Braun): CAPS, part of B. Braun, operates a national network of FDA-registered 503B outsourcing facilities supplying sterile admixture and compounded preparations to hospitals. It competes head-to-head with Empower's 503B offering in the hospital channel.
• Wedgewood Pharmacy: Wedgewood is one of the largest U.S. 503A compounding pharmacies, serving veterinarians and prescribers nationwide with personalized medications. It is the most direct 503A peer to Empower's patient-specific compounding business, sharing a similar nationwide B2B-to-provider model.

Broad incumbents

• CVS Health (Specialty/Aetna pharmacy services): CVS Health operates specialty pharmacy and care delivery businesses that increasingly overlap with personalized and compounded therapies. While not a compounder at Empower's scale, its payer-aligned infrastructure positions it as a long-term competitive threat in cash-pay-adjacent markets.
• Walgreens Boots Alliance (VillageMD / specialty pharmacy): Walgreens' specialty pharmacy and VillageMD primary care assets increasingly distribute personalized and compounded therapies through their provider networks. As a broad incumbent, it competes for prescriber mindshare and patient access in adjacent personalized-medicine categories.

Market position

Weaknesses2 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/EmpowerPharmacy

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Empower Pharmacy